(Q37600856)

English

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

scientific article published on September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors? (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

object named as

Sandra E Black

13

0 references

author name string

Roxana Oprisiu-Fournier

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sébastien Faure

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Hakim Mazouz

3

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Florent Boutitie

4

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Jean-Marie Serot

5

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Jean-Michel Achard

6

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Olivier Godefroy

7

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Olivier Hanon

8

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Mohammed Temmar

9

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Adriana Albu

10

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Svend Strandgaard

11

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Jiguang Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Albert Fournier

14

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1289-1305

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Organisation and functional role of the brain angiotensin system.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

From angiotensin IV binding site to AT4 receptor

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Megalin binds and internalizes angiotensin-(1-7).

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Direct renin inhibition with aliskiren in hypertension and target organ damage

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

(Pro)renin receptors: are they biologically relevant?

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Physiology and pharmacology of the (pro)renin receptor

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Angiotensin converting enzyme inhibitors attenuate ischemic brain metabolism in hypertensive rats.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Captopril improves neurologic outcome from incomplete cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Angiotensin and cerebral blood flow

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil: role of endogenous angiotensin II.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Ischemic injury in experimental stroke depends on angiotensin II.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Does angiotensin-II protect against strokes?

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Blood-pressure lowering for the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Results of the pilot study for the Hypertension in the Very Elderly Trial

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Secondary prevention of stroke is important: but all hypertensive drugs are not created equal?

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Blood pressure and clinical outcomes in the International Stroke Trial

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Angiotensin peptides and their pleiotropic actions

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

The angiotensin-converting enzyme gene family: genomics and pharmacology

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Renin and Its Putative Receptor Remain Enigmas

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.88

21 January 2018

Identifiers

10.1586/ERN.09.88

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37600856&oldid=1411663187"